



PIPER RUDNICK^{LLP}
1200 NINETEENTH STREET, NW
WASHINGTON, DC 20036-2412
TELEPHONE: 202-861-3900
FACSIMILE: 202-223-2085

DOCKET NO.: 3781-002-27

ASSISTANT COMMISSIONER FOR PATENTS
PO BOX 1450
ALEXANDRIA, VA 22313-1450

Re: Serial No.: 10/035,223
Applicant(s): Yong Liang CHU, et al.
Filing Date: January 4, 2002
For: COMPOUNDS FOR DELIVERING SUBSTANCES INTO CELLS
Group Art Unit: 1636
Examiner: Ramin Akhavan

SIR:


Attached hereto for filing are the following papers:

Information Disclosure Statement
International Search Report
PTO-1449
Cited Documents (7)

Our check in the amount of \$ 0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary extension of time to make the filing of the attached documents timely, please charge or credit the difference to Deposit Account No. 50-1442. Further, if these papers are not considered timely filed, then a request is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

PIPER RUDNICK LLP



Steven B. Kelber
Attorney of Record
Registration No.: 30,073

Michael Ye
Registration No.: 47,195

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION: Yong Liang CHU, et al.

GROUP ART UNIT: 1636

SERIAL NUMBER: 10/035,223

EXAMINER: Ramin Akhavan

FILED: January 4, 2002

FOR: COMPOUNDS FOR DELIVERING SUBSTANCES INTO CELLS
INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97

Assistant Commissioner for Patents
PO BOX 1450
ALEXANDRIA, VA 22313-1450

Sir:

Applicant(s) wish(es) to disclose the following information.

REFERENCES

- ☒ Applicant(s) wish(es) to make of record the documents listed on the International Search Report and the attached PTO-1449. Copies of the listed documents are attached, where required, as are either statements of relevancy or any readily available full or partial English translations of any non-English-language documents.

RELATED CASES

- ☐ Attached is a list of Applicant's(s') pending applications and issued patents which may be related to the present application. Copies of the documents, where required, are attached along with Form PTO-1449.

CERTIFICATION

The undersigned certifies that

- ☒ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application for the first time (to the knowledge of the undersigned, having made reasonable inquiry) not more than three months prior to the filing of this statement.
- ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement.

BASIS FOR CONSIDERATION

This Information Disclosure Statement is filed:


- ☐ without fee and within three months of the filing date of the application.
- ☐ without fee and within three months of the date of entry of the U.S. national stage.
- ☐ without fee and before the mailing date of a first Office Action on the merits (to the knowledge of the undersigned).
- ☒ without fee and with the appropriate certification above.
- ☐ without fee and with a new CPA application.
- ☐ without fee and with a Request for Continued Examination.
- ☐ with fee and before the mailing date of any of a Final Office Action, Notice of Allowance or an action that otherwise closes prosecution (to the knowledge of the undersigned).
- ☐ with fee, appropriate certification above, and before payment of the Issue Fee.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 50-1442.

Respectfully submitted,


PIPER RUDNICK LLP


Steven B. Kelber

Attorney of Record
Registration No. 30,073

1200 Nineteenth Street, N.W.
Washington, DC 20036-2412
Telephone No. (202) 861-3900
Facsimile No. (202) 223-2085

Michael Ye
Registration No. 47,195

Form PTO 1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	DOCKET NO. 3781-002-27	SERIAL NO. 10/035,223
		APPLICANT Yong Liang CHU, et al.	
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		FILING DATE January 4, 2002	GROUP ART UNIT 1636
U.S. PATENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE
	AA		
	AB		
	AC		
	AD		
	AE		
	AF		
	AG		
	AH		
FOREIGN PATENT DOCUMENTS			
		DOCUMENT NUMBER	DATE
	AI		
	AJ		
	AK		
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
AL	Anderson, W. French, "Human Gene Therapy", Nature, Vol. 392, Suppl. 30, pp. 25-30, April 30, 1998.		
AM	Check, E., "Cancer Fears Cast Doubts on Future of Gene Therapy", Nature, Vol. 421, p. 678, February 13, 2003.		
AN	Guo, Xin, et al., "Chemical Approaches to Triggerable Lipid Vesicles for Drug and Gene Delivery", Accounts of Chemical Research, Vol. 36, pp. 335-341, January 2003.		
AO	Juengst, Eric T., "What Next for Human Gene Therapy?", BMJ, Vol. 326, pp. 1410-1411, June 28, 2003.		
AP	McCluskie, Michael J., et al., "Direct Gene Transfer to the Respiratory Tract of Mice with Pure Plasmid and Lipid-Formulated DNA", Antisense and Nucleic Acid Drug Development, Vol. 8, pp. 401-414, November 1998.		
AQ	Templeton, Nancy Smyth, "Liposomal Delivery of Nucleic Acids in Vivo", DNA and Cell Biology, Vol. 21, pp. 857-867, November 2002.		
AR	Verma, Inder M., et al., "Gene Therapy-Promises, Problems and Prospects", Nature, Vol. 389, pp. 239-242, September 18, 1997.		
EXAMINER		DATE CONSIDERED	
<p>*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>			